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Background: Patients with cystic ﬁbrosis (CF) have a relevant morbidity and mortality caused by CF-related liver-disease. While transient
elastography (TE) is an established elastography method in hepatology centers, Acoustic-Radiation-Force-Impulse (ARFI)-Imaging is a novel
ultrasound-based elastography method which is integrated in a conventional ultrasound-system. The aim of the present study was to evaluate the
prevalence of liver-ﬁbrosis in patients with CF using TE, ARFI-imaging and ﬁbrosis blood tests.
Methods: 106 patients with CF were prospectively included in the present study and received ARFI-imaging of the left and right liver-lobe, ARFI
of the pancreas TE of the liver and laboratory evaluation.
Results: The prevalence of liver-ﬁbrosis according to recently published best practice guidelines for CFLD was 22.6%. Prevalence of signiﬁcant
liver-ﬁbrosis assessed by TE, ARFI-right-liver-lobe, ARFI-left-liver-lobe, Fibrotest, Fibrotest-corrected-by-haptoglobin was 17%, 24%, 40%, 7%,
and 16%, respectively. The best agreement was found for TE, ARFI-right-liver-lobe and Fibrotest-corrected-by-haptoglobin. Patients with
pancreatic-insufﬁciency had signiﬁcantly lower pancreas-ARFI-values as compared to patients without.
Conclusions: ARFI-imaging and TE seem to be promising non-invasive methods for detection of liver-ﬁbrosis in patients with CF.
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Liver-disease caused by liver-fibrosis is responsible for
relevant morbidity in patients with cystic fibrosis (CF) and is
present in approx. 26–45% of patients. Autopsy studies suggest
that the prevalence might even be underestimated [1]. Liver-
fibrosis can result in hepatocellular dysfunction, expansion of
extracellular matrix with distortion of hepatic architecture,
portal hypertension and finally liver-cirrhosis [2]. At present,
liver biopsy is still most commonly used as reference standard
for the assessment of liver-fibrosis. However, it is an invasive
method associated with patient discomfort and in rare casesby Elsevier B.V. All rights reserved.
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focused on the evaluation of non-invasive methods for the
assessment of liver-fibrosis. To date, most studies have evaluated
transient elastography (TE, Fibroscan®, Echosens, France) [4–6]
as well as the fibrosis blood test FibroTest (FT) [7]. At present
only few studies evaluated TE in patients with CF and concluded
that it is a useful method for non-invasive assessment of
liver-fibrosis in these patients [8–10].
Acoustic-Radiation-Force-Impulse (ARFI)-Imaging (Siemens-
Acuson-S2000) is a novel ultrasound-based elastography-method
which is integrated in a conventional ultrasound-device and can
be performed with conventional ultrasound-probes during an
abdominal ultrasound-scan. Results of a recent meta-analysis
reported good diagnostic accuracy of ARFI for assessment of
liver-fibrosis [11].
While TE can be performed in the right-lobe of the liver only
without B-mode orientation, ARFI can be performed under
B-mode orientation in both liver-lobes and therefore might
better detect focal liver-fibrosis in patients with CF. In addition,
further organs other than the liver can be evaluated with ARFI
[12].
The aim of the present study was to evaluate the prevalence
of liver-fibrosis using TE, ARFI and the fibrosis blood test
FibroTest in patients with CF and to assess pancreatic-fibrosis
using ARFI.
2. Materials and methods
The study was approved by the local ethical committee and
written informed consent was obtained from all patients and
parents (for patients aged b18 years). Between November 2009
and January 2012, 106 patients with CF aged ≥12 years were
prospectively included in the study.
All patients received conventional ultrasound, ARFI-imaging,
TE and laboratory evaluation on the same day. In addition, the
presence of CF-liver-disease (CFLD) was defined according to
recently published best practice guidelines [13]. Herefore, at least
two of the following variables need to be present: abnormal
physical examination (hepatomegaly), abnormal liver function-
test, ultrasonographic evidence of liver involvement and/or liver
biopsy diagnosis [13].
2.1. Conventional ultrasound
All patients received an ultrasound examination of the
abdomen using a convex ultrasound-probe (4C1-probe, 1–
4.5 MHz, Siemens-ACUSON-S2000, Mountain View, CA,
USA). The abdominal ultrasound included a detailed examina-
tion of the liver, spleen and pancreas assessing organ size,
echogenicity, echotexture, focal lesions, signs of liver-cirrhosis,
signs of portal hypertension, presence of ascites, and blood
flow in the portal, splenic and liver veins. Signs of liver-cirrhosis
were defined as liver surface nodularity, hypertrophy of segment
I [14]. Criteria of hepatic steatosis were hyperechogenic
parenchyma as compared to the right kidney, blurred visualiza-
tion of intrahepatic vessel walls and dorsal ultrasound attenuation
[15]. Ultrasound criteria for the severity of liver-disease inpatients with cystic fibrosis previously published [9] were used as
follows: Ultrasound-Severity-Score US1 = normal ultrasound,
US2 = homogeneous increase in echogenicity, US3 = inhomoge-
neous parenchyma, US4 = signs of liver-cirrhosis, and US5 =
inhomogeneous parenchyma (US3) or liver-cirrhosis (US4) with
signs of portal hypertension [9]. According to the literature [16]
pancreatic involvement of CF was documented if the pancreas was
hyperechoic and small as a sign of the presence of pancreatic
atrophy with replacement of the pancreatic parenchyma by fibrous
tissue and fat or if hypoechoic areas as signs of focal pancreatic
fibrosis, pancreatic calcifications and small pancreatic cysts
measuring 1–3 mm were shown.
2.2. Acoustic radiation force impulse (ARFI)-imaging
ARFI-imaging (Virtual-Touch™-Tissue-Quantification,
Siemens-ACUSON-S2000, Mountain View, CA, USA) involves
mechanical excitation of tissue using acoustic-pulses at a region-
of-interest (ROI). This leads to localized tissue-displacements
which results in shear-wave propagation away from the region of
excitation and is tracked using ultrasonic, correlation-based
methods [17]. Using the 4C1-probe the shear-wave velocity is
estimated in a central window graphically displayed with a size of
10×6 mm and results are expressed in m/s (range: 0.5–5.5 m/s).
ARFI-measurement of the liver was performed on the right-and
left-lobe of the liver. A measurement-depth of 1–2 cm below the
liver capsule was chosen to standardize the examination (Fig. 1).
This depth was chosen since TE measurement is performed
2.5 cm below the skin. Ten acquisitions at different locations
within the right and 10 within the left liver-lobe were performed
on each patient. The measurement of ARFI was performed in
different areas within the respective liver lobe to enable the
detection of focal liver fibrosis. For interpretation of ARFI-
measurements the following cut-off values of a recently published
meta-analysis were used [11]: 1.34 m/s for significant fibrosis
(Metavir-F≥2), 1.55 m/s for severe fibrosis (Metavir-F≥3), and
1.90 m/s for liver-cirrhosis (Metavir-F=4). 10 ARFI measure-
ments of the pancreas were performed in different areas of the
pancreas. Areas of macrocalcification were avoided, to prevent
overestimation of pancreatic tissue stiffness. Overall the duration
of ARFI-measurement was 10–15 min.
2.3. Transient elastography (TE)
TE was performed using Fibroscan® (Echosens, France). TE
is performed with an ultrasound transducer mounted on the axis
of a vibrator. A vibration transmitted from the vibrator towards
the tissue induces an elastic shear-wave that propagates through
the tissue. These propagations are followed by pulse-echo
ultrasound-acquisitions and their velocity is measured which is
directly related to tissue-stiffness [18]. Details have been
published in several studies [4–6]. The TE-examination takes
approx. 5 min. 10 TE-measurements were performed on the right
liver-lobe. The measurement depth is between 25 and 65 mm.
Only TE-results obtained with 10 valid measurements and with a
success-rate of at least 60%were considered reliable. The success
rate is the ratio of the number of successful TE-measurements
Fig. 1. B-mode ultrasound of the right liver-lobe using the S2000, 4C1-probe at 4 MHz probe with the ROI placed 2 cm below the liver capsule with a depth of
3.6 cm below the skin. ARFI velocity within the ROI measures 0.87 m/s.
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of 10 measurements must be valid). TE failure is defined when
less than ten valid measurements are obtained. The TE results of
all patients with at least one valid TE value were included in an
intention to diagnose analysis, while for the per protocol analysis
only patient with valid TE-values and success rate ≥60% were
included.
For interpretation of TE-measurements the following cut-off
values of a recently published meta-analysis were used [19]:
7.0 kPa for significant fibrosis (Metavir-F≥2), 9.5 kPa for
severe fibrosis (Metavir-F≥3), and 12.0 kPa for liver-cirrhosis
(Metavir-F=4).
2.4. Laboratory parameters
The following biological parameters were recorded in each
individual patient at the time of ARFI-and TE-measurements after
overnight fasting: alanine-aminotransferase (ALT), aspartate-
aminotransferase (AST), γ-glutamyl-transpeptidase (GGT),
bilirubin, alkaline phosphatase (AP), alpha-2-macroglobulin,
apolipoprotein-A1, haptoglobin, cholesterol, triglycerides, glu-
cose, amylase, lipase, C-reactive protein, and platelet count.
Enzymatic activity was measured at 37 °C in accordance with
the International Federation of Clinical Chemistry standards.
FibroMax, a commercially available modified serum fibrosis-test
was performed in each patient and computed at the Biopredictive-
website (www.biopredictive.com) [7]. Security algorithms re-
quiring the exclusion of patients at high risk for false-positive or
false-negative FibroTest results were respected. The Fibrotest was
calculated in all patients independent of the CRP. In addition,
in case of significant correlation of C-reactive-protein withhaptoglobin, a “FibroTest corrected by haptoglobin” was calcu-
lated using the median of haptoglobin (0.89 g/l).
In addition, all patients were requested to deliver a stool sample
for determination of elastase-1 enzyme. Exocrine pancreatic-
insufficiency was defined as elastase-1 levels b200 μg/g.
3. Statistical analysis
The primary statistical endpoint was to assess the prevalence
of liver-fibrosis in patients with CF using the non-invasive
methods TE, ARFI, and FibroTest. The confidence-interval to a
confidence level of 95% was used as statistical method. The
number of examined patients reflects the length of the confidence
interval. To assure that the overall length of the confidence
interval for prevalence up to 50% did not exceed 20%, at least
104 patients were calculated as a necessary sample-size.
Statistical analysis was performed with BiAS-for-Windows,
version 9.15, epsilon 2011, Frankfurt, Germany.
For TE and ARFI-imaging the median of all 10 measure-
ments per subject was calculated and used for further analysis.
Intention to diagnose and per protocol analysis was performed
for TE. For the intention to diagnose analysis all patients with at
least one valid TE value were included. For the per protocol
analysis only patient with valid TE-values and success rate
≥60% were included.
Correlations were assessed by Spearman's correlation coeffi-
cient. Comparison of different groups and methods was performed
using the non-parametric Wilcoxon–Mann–Whitney-U-Test
(two-sides, level of significance α=5%) for quantitative values.
For comparison of different methods within the same patient group
the non-parametric Wilcoxon-matched-pairs-test (two-sides, level
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Cochran–Mantel–Haenszel-Test was performed to compare
fibrosis prevalence in two or more independent patient groups.
To evaluate the association of all non-invasive methods the
non-parametric Friedman test used. The agreement of the single
methods with each other was performed using the Conover-
method with Bonferroni–Holmes adjusted p-values (level of
significance α=5%). The higher the p-value the higher is the
agreement of two methods.
The diagnostic performance of TE, ARFI-imaging, and
FibroTest for the diagnosis of CFLD according to the recently
published best practice guidelines [13] was assessed by receiver-
operating-characteristic (ROC)-curves. The ROC-curve repre-
sents sensitivity versus 1-specificity for all possible cut-off values
for prediction of the different fibrosis stages, respectively. The
areas-under-the-ROC-curves (AUROC) as well as 95%-CI of
AUROC were calculated. Cut-off values for the prediction of
CFLD were defined using Youden's index. The optimal cut-off
was defined as the cut-off with the highest sum of sensitivity and
specificity.
4. Results
A total of one-hundred-six consecutive patients were included
in the study. Patient characteristics are shown in Table 1.
Mutations in the gene cystic fibrosis transmembrane conductance
regulator (CFTR) were distributed as follows: fifty-six patients
(52.8%) with two severe mutations (classes I–III and VI), 28
(26.4%) patients with one severe mutation and one unknown
mutation, 11 (10.4%) patients with one severe and one mild
mutation (class IV–V), 11 (10.4%) patients without known
mutations on both alleles. In 5 (4.7%) patients no mutations were
identified and in 6 (5.7%) patients mutation-analysis was not
available at study inclusion. However, all 11 patients had a repeat
pilocarpine-iontophoresis sweat test previously with pathological
results establishing the diagnosis of CF. The prevalence of
liver-fibrosis according to recently published best practice
guidelines for CFLD was 22.6% [13].
4.1. Conventional ultrasound
In 56 (52.8%) patients ultrasound signs of simple steatosis
hepatitis were observed. In 66 (62.3%) patients abdominal
ultrasound revealed changes in echogenicity/echotexture of the
liver as a sign of diffuse parenchymal damage (US-Score 2–5).
In 9 of these patients signs of liver-cirrhosis were present. None
of the patients had ascites. US-Score were found as follows: 40
patients with US-1 (normal liver), 30 with US-2, 25 with US-3,
2 with US-4, and 9 with US-5. Focal liver lesions were found in
4 patients, hemangioma in 2 of these patients and liver cysts in
the other two patients.
No significant difference in the prevalence of liver-cirrhosis
was found between patients with one or two severe mutations
(9.1% vs. 10.7%, p=0.94).
In 89 (83.9%) patients changes in echogenicity, echotexture
and/or size of pancreas were found. Pancreatic atrophy was
observed in overall 49 (46.2%) patients, and increase in size in1 patient, and hyperechogenic parenchyma in 83 patients. Overall,
in 75 (70.7%) patients parenchymal changes were suggestive of
pancreatic involvement by typical ultrasound changes reported in
CF patients, with the presence of calcifications in 5 (4.7%) patients
and cystic-lesions in 3 (2.8%) patients.
4.2. TE
In 4 (3.8%) patients no valid TE-measurement could be
obtained. The skin to liver-capsule distance was greater than
2.5 cm in all 4 patients. Therefore, 102 patients could be included
in the intention to diagnose analysis of TE. In addition, in 21
(19.8%) patients unreliable TE-values (success rateb60%) were
documented. Therefore, TE was available for per protocol
analysis in only 81 patients. Details on values and fibrosis
distribution are shown in Table 1, Fig. 2 and Supplementary
Table 3. TE-values were significantly higher in male than female
patients (4.6 kPa vs. 3.9 kPa, p=0.017). No significant differ-
ence in TE-values was found between patients with one or two
severe mutations (p=0.64). Correlations are shown in Supple-
mentary Table 1. When using the accepted criteria for the
diagnosis of CFLD [13] as reference for the presence of CFLD,
the diagnostic accuracy of TE was 63% (95%-CI: 48%; 79%).
The optimal cut-off was 7.1 kPa with a sensitivity and specificity
of 45.83% and 91.36%, respectively.
4.3. ARFI-liver
ARFI-measurement of the right liver-lobe could be
performed successfully in all patients. ARFI-measurement failure
of the left liver-lobe was documented in one patient with BMI of
28 kg/m2 and difficult access of the left liver-lobe by ultrasound.
Details on values and fibrosis distribution are shown in Table 1,
Fig. 2 and Supplementary Table 3. ARFI-measurements of the
left liver-lobe were significantly higher than ARFI-measurements
of the right liver-lobe (1.29 m/s vs. 1.17 m/s, p=0.000002).
Agreement concerning the fibrosis stage was found in 70 of 105
patients (67%) for ARFI-measurement in the right and left
liver-lobe (Cohen's Kappa=0.33, p=0.000001). ARFI-values in
the right liver-lobe were significantly higher in male patients than
female patients (1.21 m/s vs. 1.11 m/s, p=0.0026), ARFI-values
in the left liver-lobe did not show significant gender difference
(1.31 m/s vs. 1.28 m/s, p=0.56). While no significant difference
in ARFI-values from the right liver-lobe was found between
patients with one or two severe mutations (p=0.37), ARFI-values
from the left liver-lobe were significantly higher in patients with
one severe mutation as compared to patients with two severe
mutations (1.46 m/s vs. 1.28 m/s, p=0.027). Correlations are
shown in Supplementary Table 1. When using the accepted
criteria for the diagnosis of CFLD [13] as reference for the
presence of CFLD, the diagnostic accuracies of ARFI of the right
and left liver lobe were 72% (95%-CI: 58%; 86%) and 71%
(95%-CI: 59%; 84%), respectively. The optimal cut-off for ARFI
of the right liver lobe was 1.42 m/s with a sensitivity and
specificity of 54.17% and 93.90%, respectively. The optimal
cut-off for ARFI of the left liver lobe was 1.45 m/s with a
sensitivity and specificity of 54.17% and 86.59%, respectively.
Table 1
Patient characteristics.
Patient characteristics All patients (n=106) Patients without CFLD (n=82) Patients with CFLD (n=24) p-value
Age (years), median; mean±SD (range) 29; 29.9±10.8 (12–60) 29; 29.8±10.4 (12–60) 29.5; 30.5±12.7(12–53) 0.85
Age at diagnosis (years), mean±SD (range) 5.3±9.6 (1 month–45 years) 1.8±19.9 (1 month–45 years) 3.4±4.9 (1 month–17 years) 0.69
Male sex, n (%) 65 (61.3) 50 (61.0) 15 (62.5) 0.89
Body mass index (BMI), mean±SD (range) 20.6±2.9 (15.5–34.9) 20.8±3.0 (15.5–34.9) 21.6±5.9 (16.0–44.5) 0.90
Pulmonary function
FVC (%), mean±SD (range) 78±20 (41–131) 78±20 (41–131) 77±21 (41–131) 0.78
FEV1 (%), mean±SD (range) 61±24 (20–123) 61±24 (21–123) 61±24 (20–103) 0.91
Pancreatic-insufficiency, n (%) 91 (85.8) 68 (82.3) 23 (95.8) 0.11
Diabetes mellitus, n (%) 28 (26.4) 20 (24.4) 8 (33.3) 0.38
Homocygote mutation ΔF508, n (%) 42 (39.6) 33 (40.2) 9 (37.5) 0.88
Heterocygote mutation ΔF508, n (%) 47 (44.3) 37 (45.1) 10 (41.7) 0.77
AST (xULN), mean±SD (range) 0.84±0.46 (0.35–3.33) 0.74±0.36 (0.35–3.33) 1.16±0.61 (0.45–3.08) 0.00010
ALT (xULN), mean±SD (range) 0.79±0.64 (0.14–4.86) 0.67±0.42 (0.14–2.18) 1.20±1.02 (0.20–4.86) 0.0057
GGT (xULN), mean±SD (range) 0.71±1.13 (0.08–6.68) 0.49±0.75 (0.13–6.52) 1.46±1.78 (0.08–6.68) 0.0021
Bilirubin (mg/dl), mean±SD (range) 0.59±0.41 (0.20–2.90) 0.56±0.32 (0.20–2.00) 0.66±0.6 (0.32–0.87) 0.65
Alkaline Phosphatase (mg/dl), mean±SD (range) 140±117 (29–675) 108±58 (29–486) 234±189 (60–675) 0.00030
Albumin (g/dl), mean±SD (range) 4.72±4.02 (2.70–45.5) 4.86±4.56 (3.0–45.5) 4.26±0.59 (2.70–5.20) 0.98
Platelet count (nl−1), mean±SD (range) 277±77 (94–523) 287±80 (139–523) 242±53 (94–340) 0.019
INR, mean±SD (range) 1.06±0.09 (0.88–1.48) 1.05±0.09 (0.88–1.28) 1.07±0.12 (0.93–1.48) 0.62
Amylase (U/l), mean±SD (range) 60±70 (9–687) 64±77 (9–687) 51±17 (9–83) 0.96
Lipase (U/l), mean±SD (range) 20±25 (5–142) 22±27 (5–142) 15±14 (7–62) 0.42
Sonographic signs of liver-cirrhosis, n (%) 9 (8.5) 1 (1.2) 8 (33.3) 0.000001
Sonographic signs of portal Hypertension, n (%) 8 (7.6) 0 (0.0) 8 (33.3) b0.000001
Ultrasound Severity Score [9] mean±SD (range) 2; 2.15±1.20 (1–5) 2; 1.72±0.79 (1–2) 3; 3.54±1.18 (1–5) b0.000001
US-Score=1, n (%) 40 (37.7) 39 (47.6) 1 (4.2) –
US-Score=2, n (%) 30 (28.3) 28 (34.1) 2 (8.3) –
US-Score=3, n (%) 26 (24.5) 14 (17.1) 12 (50.0) –
US-Score=4, n (%) 2 (1.9) 1 (1.2) 1 (4.2) –
US-Score=5, n (%) 8 (7.6) 0 (0.0) 8 (33.3) –
Fibroscan (kPa), median; mean±SD (range) 4.4; 5.6±3.5 (2.5–28.4) 4.3; 4.8±1.6 (2.5–10.1) 6.7; 8.5±6.2 (2.8–28.4) 0.049
ARFI-right liver-lobe (m/s), median; mean±SD (range) 1.17; 1.21±0.21 (0.88–2.12) 1.15; 1.16±0.14 (0.88–1.48) 1.43; 1.40±0.32 (0.91–2.12) 0.00070
ARFI-left liver-lobe (m/s), median; mean±SD (range) 1.29; 1.34±0.29 (0.85–2.54) 1.27; 1.28±0.24 (0.85–2.54) 1.46; 1.52±0.35 (0.90–2.21) 0.0012
ARFI pancreas (m/s), median; mean±SD (range) 0.89; 0.91±0.20 (0.64–2.02) 0.89; 0.90±0.20 (0.64–2.02) 0.90; 0.95±0.19 (0.68–1.40) 0.022
CFLD = Cystis Fibrosis Liver Disease according to present guidelines; SD = standard deviation, FVC = forced vital capacity, FEV1 = forced expiratory volume in one second, ULN = upper limit of normal, AST = aspartate-
aminotransferase, ALT = alanine-aminotransferase and GGT = gamma-glutamyl-transpeptidase.
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Fig. 2. Histogram for the prevalence of liver-fibrosis stages (%) using Transient Elastography, ARFI-imaging, and Fibrotest. The following abbreviations were used:
TE-itd = results for transient elastography according to the intention to diagnose analysis; TE-pp = per protocol results of transient elastography; ARFI-rll = ARFI of
the right liver lobe; ARFI-lll = ARFI of the left liver lobe; FT = Fibrotest; and FT-cbh = Fibrotest corrected by haptoglobin.
Table 2
Difference of fibrosis prevalence assessed with TE, ARFI-right liver, ARFI-left
liver and FibroTest in patients with cystic fibrosis.
Method 1 Method 2 p-value a
Transient elastography ARFI-right liver 0.97
Transient elastography ARFI-left liver 0.00027
Transient elastography FibroTest 0.0069
Transient elastography FibroTest (corrected) 0.43
ARFI-right liver FibroTest 0.0069
ARFI-left liver FibroTest b0.000001
ARFI-right liver ARFI-left liver 0.00028
ARFI-right liver FibroTest (corrected) 0.43
ARFI-left liver FibroTest (corrected) 0.000001
FibroTest FibroTest (corrected) 0.29
a Valid TE-measurements were available in 102/106 patients only, therefore
calculation was performed in 102 patients.
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Elevated ALT, AST, FFT, alkaline-phosphatase (AP) or
bilirubin was documented in 40 of 106 (38%) patients. In 18
(17%) patients cholestatic-enzymes and transaminases were
elevated (AST, ALT, GGT, AP, bilirubin). While a significant
correlation could be found for C-reactive protein (CRP) with
haptoglobin (r=0.38, p=0.000083), no significant correlation
was found for CRPwith alpha-2-macroglobuline. The prevalence
of significant liver-fibrosis using the FibroTest was 6.6%,
however using the Fibrotest corrected by haptoglobin the
prevalence increased to 16%. Details on fibrosis distribution are
shown in Fig. 2 and Supplementary Table 3. Necroinflammatory
activity measured with the ActiTest was observed in 27 (26%)
patients. The SteatoTest could be calculated in 105/106 patients
and steatosis was found in 13/105 (12.4%) patients. Correlations
of FibroTest, ActiTest and SteatoTest are shown in Supplemen-
tary Table 2.
When using the accepted criteria for the diagnosis of CFLD
[13] as reference for the presence of CFLD, the diagnostic
accuracies of Fibrotest and Fibrotest corrected by haptoglobin
were 64% (95%-CI: 49%; 78%) and 62% (95%-CI: 47%; 76%),
respectively. The optimal cut-off for Fibrotest was 0.21 with a
sensitivity and specificity of 37.50% and 90.24%, respectively.
The optimal cut-off for Fibrotest corrected by haptoglobin was
0.27 with a sensitivity and specificity of 39.13% and 87.65%,
respectively.4.5. Comparison of non-invasive methods for the diagnosis of
liver-fibrosis
The highest prevalence of significant liver-fibrosis was
shown using ARFI-imaging of the left liver-lobe (ARFI-left-
liver), the lowest using the standard FibroTest. The prevalence
of significant fibrosis and the single fibrosis-stages are shown in
Fig. 2 and Supplementary Table 3. The Friedman-test revealed
significant differences between TE, ARFI-left liver, ARFI-right
liver and FibroTest results concerning fibrosis prevalence
(Friedman's Chi2 =52.84; pb0.000001). The post-hoc-analysis
Table 3
Comparison of patients with pancreatic-insufficiency and patients without.
Diabetis mellitus, n (%)
ARF-pancreas-failure, n (%)
ARF-pancreas (m/s)
mean ± SD (range)
Lipase (U/I)
Alkaline phosphatase (U/I)
Amylase (U/I)
mean ± SD (range)
mean ± SD (range)
mean ± SD (range)
mean ± SD (range)
mean ± SD (range)
mean ± SD (range)
mean ± SD (range)
ApolipoproteinA1 (mg/dl)
Cholesterol (mg/dl)
Vitamin D3 (mg/dl)
Alpha-2-macroglobulin (mg/dl)
Pancreatic-
27 (29.7%)
7 (6.6)
0.88 ± 0.16 (0.63–1.46)
53 ± 29 (9–190)
14 ± 15 (5–102)
135 ± 37 (60–318)
213 ± 53 (110–351)
135 ± 35 (69–311)
152 ± 123 (29–675)
21 ± 13 (4–77)
insufficiency (n = 91)
No pancreatic-
insufficiency (n = 15)
1 (0.9%)
0 (0.0)
1.07 ± 0.31(0.75–2.02)
111 ± 157 (41–687)
61 ± 31 (25–142)
162 ± 47 (95.5–293)
174 ± 39 (104–248)
184 ± 46 (112–277)
69 ± 17 (40–110)
14 ± 8 (4–30) 0.075
<0.000001
<0.00041
0.0071
0.020
<0.000001
0.0053
0.0031
0.27
0.062
p-value
Non-significant correlations are shown in gray, while significant correlations
are shown in black letters ARFI = acoustic radiation force impulse-imaging; and
SD = standard deviation.
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differences between the results of TE and standard FibroTest, TE
and ARFI-left liver, standard FibroTest and ARFI-right liver,
standard FibroTest and ARFI-left liver, and ARFI-right liver and
ARFI-left liver, respectively. However, no significant difference
of fibrosis prevalence was found using TE and ARFI-right liver,
TE and FibroTest-corrected-by-haptoglobin and ARFI-right liver
and FibroTest-corrected-by-haptoglobin. Details of the intention
to diagnose analysis are shown in Table 2.
4.6. ARFI-pancreas
ARFI-measurement could be successfully performed in 99
(93.4%) patients. Reasons for unsuccessful measurements were:
3 patients with pancreatic atrophy (pancreatic parenchyma too
small to allow placement of the ROI), 3 patients with adipositas,
and one patient with severe abdominal pain refusing pancreatic
ultrasound. Values are shown in Table 1. No significant
difference in ARFI-pancreas values was found between patients
with one or two severe mutations (p=0.10). A significant
correlation of ARFI-imaging was found with the daily dose of
pancreatic enzymes (r=−0.29, p=0.0071), serum lipase (r=
0.30, p=0.0030) and ARFI-left liver-lobe (r=0.22, p=0.027).
A fresh stool probe for evaluation of −1 was available in 57 of
106 (54%) patients during the study period. In 43 of 57 (75%)
patients elastase-1 measured b200 μg/g and herewith the
diagnosis of exocrine pancreatic-insufficiency was assumed. In
addition, all patients had previously been evaluated for pancreatic
insufficiency. ARFI-measurement in the pancreas was signifi-
cantly lower in patients with pancreatic-insufficiency as com-
pared to patients without (0.88 vs. 1.07, p=0.0031) (Table 3).
5. Discussion
CF-associated focal andmultilobular liver-fibrosis and cirrhosis
are the most frequent causes of extrapulmonary mortality in
patients with cystic fibrosis [20,21]. Liver-fibrosis and -cirrhosis in
patients with CF can result from liver-steatosis, congested liver
due to lung fibrosis with chronic right heart-insufficiency, as well
as from focal biliary-fibrosis and -cirrhosis which can lead to
multilobular biliary-cirrhosis [22].
In the present study 53% of patients had sonographic signs
of liver-steatosis. The results are in accordance with previous
ultrasound studies reporting steatosis in 30–46% of patients
with CF [23]. The prevalence of significant liver-fibrosis in
patients with CF in the present study was 16–24% and was best
determined with TE, ARFI of the right liver-lobe and FibroTest-
corrected-by-haptoglobin. This prevalence is in accordance with
recent studies reporting a prevalence of 26–45% using clinical,
biochemical and imaging diagnostic-criteria [24]. Prevalence
of liver-cirrhosis was 8.5% in the present study which is in
accordance with previous studies reporting prevalences of 5–
11% [23].
The Cystic-Fibrosis-Foundation-Hepatobiliary-Consensus-
Group recommends clinical and laboratory evaluation once yearly
in patients with CF [22]. In addition to this the European-
Consensus-on-Standards-of-Care recommends annual ultrasound-evaluation for early detection of hepatobiliary involvement [25].
Using the CFLD-best practice guideline [13] recently published
for the diagnosis of CFLD, a prevalence of CFLD of 23% was
revealed in the present study. This prevalence is in accordance
with the prevalence found with the elastography and the Fibrotest.
Using these CFLD criteria as reference method, the diagnostic
accuracies of TE, ARFI-right liver lobe, ARFI-left liver lobe,
Fibrotest, and Fibrotest-corrected by-haptoglobin were 63%,
72%, 71%, 64%, and 62%, respectively. However laboratory
values often do not correlate with the stage of liver-fibrosis
and conventional ultrasound can detect liver-cirrhosis, however
differentiation of mild and severe fibrosis is not possible.
Therefore, non-invasive ultrasound-based methods such as TE,
ARFI and FT might further improve diagnosis of liver-fibrosis in
CF-patients by combining them with the well accepted CFLD
criteria. Possibly these non-invasive methods could be included in
the yearly longitudinal follow-up of individual patients to improve
the early detection of liver fibrosis. The advantage of ARFI over
TE is that it is integrated in a conventional ultrasound system and
can be performed in different locations within the liver possibly
better assessing focal biliary-fibrosis as is typical for CF.
Nevertheless, it might also lead to an overestimation of the
number of patients with CF liver disease, if few areas of focal liver
fibrosis are measured for the estimation of overall liver fibrosis.
This might account for the higher percentage of significant liver-
438 M. Friedrich-Rust et al. / Journal of Cystic Fibrosis 12 (2013) 431–439fibrosis detected with ARFI (24%) versus TE (17%). However,
studies with histology as reference method would be necessary to
further evaluate this assumption. In addition, the costs of a TE-
machine are approx. half the price of an ultrasound machine
including ARFI.
Haptoglobin as a component to calculate the FibroTest
significantly correlated with C-reactive-protein as a marker of
inflammation, which is often present in CF-patients. Therefore,
the standard FibroTest seems less useful in this setting as
shown by the results of the study with an underestimation of
liver-fibrosis (6.6%) in CF-patients. However, when correcting
for haptoglobin the prevalence of liver-fibrosis measured with
FibroTest increased to 16%, which is comparable to the fibrosis
prevalence measured with TE and ARFI. Nevertheless, the
value of the Fibrotest corrected for haptoglobin needs further
evaluation in other clinical inflammatory settings in future
studies to further evaluate this assumptions.
Mean TE-values in the present study (5.6 kPa) were compa-
rable to two previous studies evaluating TE in patients with CF
(5.3–5.6 kPa) [9,10]. TE and ARFI-values were significantly
higher in male patients than female patients (TE: p=0.017; ARFI:
p=0.0026). Male patients are known to have a higher prevalence
of CF-associated liver-fibrosis [20] and this was supported by the
results of the present study. However, a previous study have
reported higher TE-values for male than female subjects even in
429 healthy-subjects [26], while no such association has been
reported for ARFI [27]. Mean ARFI-values were 1.21 m/s in
the right liver-lobe and 1.34 m/s in the left liver-lobe. The results
are in accordance with a small study reporting ARFI-values of
1.10 m/s in 28 CF-patients without portal hypertension and
1.56 m/s in 12 CF-patients with portal hypertension [28].
ARFI-values measured in the left liver-lobe were significantly
higher than in the right liver-lobe in the present study. This
coherence has been reported in ARFI-studies in chronic liver-
disease, and ARFI-values of the right liver-lobe showed better
diagnostic accuracy for the diagnosis of liver-fibrosis [29]. Since
ARFI is integrated in a conventional ultrasound system, the ROI
for measurement can be placed in different areas within the liver as
compared to TE. Since biliary fibrosis in CF can be focal only, it
can be missed by TE. However, literature on this assumption is
missing. Possibly the combination of B-mode ultrasound with
ARFI could improve the detection of focal biliary fibrosis.
However, this assumption needs further evaluation in future
studies.
In the present study pancreatic-insufficiency was present in
86% of patients, which is comparable to the prevalences reported
in previous studies with 79–92% [30]. ARFI-measurement in the
pancreas was significantly lower in patients with pancreatic-
insufficiency as compared to patients without. Since ARFI
measures stiffness, patients with pancreatic-insufficiency had
softer, and possibly more fat than fibrotic replacement of
pancreatic parenchyma (0.90 m/s vs. 1.08 m/s). However, this
assumption needs further evaluation in future studies. ARFI-
values of the pancreas were lower in all CF-patients as compared
to a recent study in healthy subjects measuring 1.22–1.40 m/s
[12]. In patients with chronic pancreatitis values between 1.25
and 2.05 m/s have been reported [31]. Pancreatic atrophy andfatty infiltration might account for the softer tissue in patients
with CF. Future studies should further evaluate these coherences.
A limitation of the present study is the missing of a reference
standard such as histology. The cut-offs used for diagnosing
liver-fibrosis were obtained from meta-analyses. However they
must not necessarily be transferrable to CF liver-disease.
However, neither the CFLD-Ultrasound Scoring System (Menten
et al. [9]) nor the definition criteria of CFLD [13] were validated
using liver biopsy as reference in all patients. Nevertheless, we
also defined cut-offs using the definition criteria of CFLD as
reference method. In addition, we calculated the prevalence of
significant liver fibrosis using cut-offs for chronic liver disease
evaluated using liver biopsy as reference method in large patient
groups using histology as reference method [4,11,19] and best
agreement was found for TE, ARFI of the right liver-lobe and
FibroTest-corrected-by-haptoglobin. The aim of the non-invasive
tools is not to replace, but rather supplement the present
diagnostic guidelines for the diagnosis of liver-fibrosis in
CF-patients. In addition, only patients aged 12 years and older
were included in the present study, as suggested by the local
ethical committee. Possibly evaluation at an even younger age
could be useful for early assessment of illness. Unfortunately, the
non-invasive elastography methods can not differentiate between
portal hypertension and liver fibrosis, since elastography values
increase both with increasing liver fibrosis and with increasing
hepatic-venous-pressure gradient.
In conclusion, ARFI-imaging of the right liver-lobe, TE and
FibroTest-corrected-by-haptoglobin seem to be promising non-
invasive methods for detection of liver-fibrosis in patients with
CF. The prevalence of significant liver-fibrosis was 16–24%,
respectively. ARFI-imaging has the advantage over TE of higher
success-rate, and its integration in a conventional ultrasound-
system.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.jcf.2012.12.013.References
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